Guggenheim Capital LLC Editas Medicine, Inc. Transaction History

Guggenheim Capital LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $125,740 - $199,642	15,113 Added 30.23%	65,112 $577,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $162,944 - $260,228	-13,400 Reduced 21.14%	49,999 $612,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $87,302 - $186,577	8,739 Added 15.99%	63,399 $750,000
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $167,425 - $328,548	11,891 Added 27.8%	54,660 $1.04 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $361,823 - $552,887	13,628 Added 46.77%	42,769 $1.14 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $414,377 - $769,662	-10,552 Reduced 26.58%	29,141 $1.2 Million
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $78,975 - $142,959	2,524 Added 6.79%	39,693 $2.25 Million
Q1 2021 May 13, 2021	BUY	$39.71 - $90.58 $1.48 Million - $3.37 Million	37,169 New	37,169 $1.56 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $1.31 Million - $2.28 Million	-71,863 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $133,466 - $185,308	4,827 Added 7.2%	71,863 $2.29 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $350,235 - $457,425	11,154 Added 19.96%	67,036 $2.4 Million
Q1 2018 May 15, 2018	SELL	$29.84 - $44.08 $584,804 - $863,879	-19,598 Reduced 25.96%	55,882 $1.85 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $1.65 Million - $2.37 Million	75,480	75,480 $2.32 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.